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Background: Fork head box M1 (FoxM1) is a proliferation-associated transcription factor essential for cell cycle
progression. Numerous studies have documented that FoxM1 has multiple functions in tumorigenesis and its
elevated levels are frequently associated with cancer progression. The present study was conducted to investigate
the expression of FoxM1 and its prognostic significance in clear cell renal cell carcinoma (ccRCC). Meanwhile, the
function of FoxM1 in human ccRCC was further investigated in cell culture models.
Methods: Real-time quantitative PCR, western blot and immunohistochemistry were used to explore FoxM1
expression in ccRCC cell lines and primary ccRCC clinical specimens. FoxM1 expression was knocked down by small
interfering RNA (siRNA) in Caki-1 and 786-O cells; proliferation, colony formation, cell cycle, migration, invasion, and
angiogenesis were assayed.
Results: FoxM1 expression was up-regulated in the majority of the ccRCC clinical tissue specimens at both mRNA
and protein levels. Clinic pathological analysis showed that FoxM1 expression was significantly correlated with
primary tumor stage (P <0.001), lymph node metastasis (P = 0.01), distant metastasis (P = 0.01), TNM stage (P < 0.001)
and histological grade (P = 0.003). The Kaplan–Meier survival curves revealed that high FoxM1 expression was
associated with poor prognosis in ccRCC patients (P < 0.001). FoxM1 expression was an independent prognostic
marker of overall ccRCC patient survival in a multivariate analysis (P = 0.008). Experimentally, we found that
down-regulation of FoxM1 inhibited cell proliferation and induced cell cycle arrest with reduced expression of
cyclin B1, cyclin D1, and Cdk2, and increased expression of p21 and p27. Also, down-regulation of FoxM1 reduced
expression and activity of matrix metalloproteinase-2 (MMP-2), MMP-9 and vascular endothelial growth factor
(VEGF), resulting in the inhibition of migration, invasion, and angiogenesis.
Conclusions: These results suggest that FoxM1 expression is likely to play important roles in ccRCC development
and progression, and that FoxM1 is a prognostic biomarker and a promising therapeutic target for ccRCC.
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Renal cell carcinoma (RCC) accounts for approximately
3% of all adult malignancies and represents the most le-
thal urological cancer [1]. Approximately 60,920 new
cases of RCC were diagnosed in the United States in
2011, with an estimated 13,120 deaths [2]. Worldwide,
the incidence of RCC is over 200,000 new cases annu-
ally, with over 100,000 deaths per year [3]. Clear cell
RCC (ccRCC) is the most common histological subtype,
comprising 70–80% of all RCC cases [4]. Nearly 25-30%
of patients with RCC have evidence of metastases at ini-
tial presentation [5,6]. Although radical nephrectomy is
effective to cure early and local RCCs, 30% of patients
develop metastatic disease after surgery [7]. Patients
with metastatic RCC face a dismal prognosis and have
limited therapeutic options. Median survival in a recent
cohort was only 1.5 years with fewer than 10% of
patients surviving to 5 years [8]. Therefore, it is of para-
mount importance to better understand the pathogen-
esis of aggressive RCC in order to develop effective
strategies for the prevention and treatment of RCC.
Fork head Box M1 (FoxM1) is a member of the Fork
head Box family of transcription factors that share a
conserved winged helix DNA binding domain [9].
FoxM1 is ubiquitously expressed in all proliferating cells,
including many tumor-derived cell lines. In normal tis-
sues, FoxM1 is detectable in progenitors with extensive
proliferating capacity while its expression is extinguished
in differentiated or resting cells [10,11]. FoxM1 is known
to be a key cell cycle regulator of both the transition
from G1 to S phase and the progression to mitosis by
regulating transcription of cell cycle genes, including
cyclin B1, cyclin D1, Cdc25A, Cdc25B, aurora B kinase,
surviving, p21Cip1, and p27Kip1 [12-17]. Loss of FoxM1
expression has been reported to generate mitotic spindle
defects leading to mitotic catastrophe [16-18].
Recent data from several groups have highlighted that
FoxM1 is up-regulated in a wide variety of cancers such
as basal cell carcinomas, prostate cancer, glioblastomas,
gastric cancer, breast cancer, and lung cancer [19-24].
More importantly, the increased expression of FoxM1
has been correlated with clinically aggressive behavior
and patient survival in numerous human cancers [25-30].
Hence, FoxM1 not only promotes tumorigenesis by
endowing proliferative capacity and leading to uncon-
trolled cell division at the early period of cancer develop-
ment but also enhances other tumorigenic behaviors in
other stages of cancer development. Indeed, recent evi-
dence has implicated FoxM1 in several other cancer-
related processes such as angiogenesis, invasion, and
metastasis. For instance, FoxM1 was shown to stimu-
late invasion and angiogenesis of pancreatic cancer
cells through induction of matrix metalloproteinase
MMP-2 and MMP-9, as well as vascular endothelialgrowth factor (VEGF) [31]. Similar functions of
FoxM1 in stimulating expression of MMP-2 and MMP-9
have also been documented in other malignancies, such as
glioblastoma [32], breast carcinoma [33], and colorectal
carcinoma [34]. Moreover, overexpression of FoxM1 coin-
cides with metastasis of prostate cancer [35]. Furthermore,
the mechanistic studies by Park et al. suggested that
FoxM1 could function as a master activator of metastasis
in nude mice, as it induced various steps of metastasis
[36]. The study demonstrated that in the absence of Arf,
FoxM1 overexpression contributes directly to metastatic
behavior by driving the epithelial-mesenchymal transition
through Akt, disrupting the rigidity of the cytoskeleton by
upregulating the microtubule destabilizing protein Stath-
min, and promoting the formation of pre-metastatic
niches at distant organs by upregulating the lysyl oxidase
collagen cross-linking proteins LOX and LOX2. These
results indicate that FoxM1 may play diverse roles in can-
cer progression and that it could be a promising thera-
peutic target.
However, the expression pattern, clinical relevance,
and biological function of FoxM1 in ccRCC have so far
not been investigated. In the present study, we examined
both mRNA and protein expression patterns in ccRCC
tissues. We also investigated the correlations between
FoxM1 expression and various clinic pathologic para-
meters, and its prognostic value for survival of patients
with ccRCC. Then, we employed the small interfering
RNA (siRNA) technique to evaluate the effects of knock-
down of FoxM1 on proliferation, migration, invasion
and angiogenesis of ccRCC cell lines in vitro. Together,
our data highlight an important role for FoxM1 in
controlling ccRCC progression.
Methods
Patients and surgical specimens
A total of 83 primary ccRCC tissues and matched adja-
cent nontumor renal tissues were obtained from patients
who underwent radical nephrectomy in the Department
of Urology, First Affiliated Hospital of Gannan Medical
University between 2004 and 2008. None of the patients
had received chemotherapy or radiotherapy before sur-
gery. After surgical resection, tumor specimens and cor-
responding adjacent nontumor tissues were collected
and stored in liquid nitrogen until use. Parts of each
sample were fixed in formalin, embedded in paraffin and
stored in the Department of Pathology, First Affiliated
Hospital of Gannan Medical University. Fourty-five of
these 83 patients were men and 38 were women. The
median age of the patients was 57 years (range, 31-
76 years). The median follow-up time was 53.2 months
(range, 4-78 months). Information on gender, age, stage
of disease, and histopathologic factors was abstracted
from the medical records. All of the tumors were
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of the hospital. All of the cases were staged according to
the tumor node metastasis staging system and nuclear
grade was evaluated on the basis of the Fuhrman cri-
teria. Patients’ data are summarized in Table 1. For the
use of these clinical materials for research purposes,
prior patient’s consent and approval from the Institute
Research Ethics Committee were obtained.Immunohistochemistry staining
All samples were fixed in 10% formaldehyde solution,
embedded in paraffin blocks, cut in 4-μm-thick sections,
and mounted on glass slides. Each slide was dewaxed in
xylene and rehydrated in grade alcohol, followed by boil-
ing in 10 mmol/L of citrate buffer (pH 6.0) for antigen
retrieval. After inhibition of endogenous peroxidase ac-
tivities for 30 minutes with methanol containing 0.3%
H2O2, the sections were blocked with 2% bovine serum
albumin for 30 minutes and incubated overnight at 4°C
with primary polyclonal rabbit anti-human FoxM1 anti-
body (Santa Cruz Biotechnology Inc, Santa Cruz, CA,
USA; 1: 50 dilution). After washing thrice with PBS, the
slides were incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG for 30 minutes, followed
by reaction with diaminobenzidine and counterstainingTable 1 FoxM1 protein expression in 83 ccRCC tissues
determined by immunohistochemistry
Variable Total FoxM1 exression P-value
Low High
Age,years (median 57)
<57 41 23 18 0.533
≥57 42 22 20
Gender
Male 51 27 24 0.473
Female 32 18 14
T stage
T1-2 61 41 20 <0.001
T3-4 22 4 18
N stage
N0 71 43 28 0.01
N1-2 12 2 10
M stage
M0 74 44 30 0.01
M1 9 1 8
Histological grade
G1-2 52 35 17 0.003
G3-4 31 10 21
TNM stage
I-II 56 59 17 <0.001
III-IV 27 6 21with Mayer0 hematoxylin. Negative control was done by
omission of the primary antibody and substituting it
with nonspecific rabbit IgG.
Evaluation of immunohistochemical staining
Three pathologists (H.Y., S.P. and X.H.) evaluated the
immunostaining in a blinded fashion without any know-
ledge of the clinical outcome or other clinicopathological
data. If there was a discrepancy in individual evaluations,
then all the three pathologists reevaluated the slides to-
gether to reach a consensus. Immunohistochemical stain-
ing of FoxM1 was evaluated using a semi-quantitative
scoring system for both staining intensity and the percent-
age of positive cells. A score was calculated by multiplying
the intensity (negative scored as 0, mild scored as 1, mod-
erate scored as 2 and strong scored as 3) by percentage of
stained cells (0, < 5%; 1, 5–25%; 2, 26–50%; 3, 51–75%;
and 4, 76–100%). Scores of multiplication were graded as
follows: −, 0; +, 1–3; ++, 4–8; +++, 9–12. Additionally, for
statistical analysis, the − and 1+ cases were pooled into the
low-expression group, and the 2+ and 3+ cases were
pooled into the high-expression group.
Cell lines
Human RCC cell lines 786-O and Caki-1 were pur-
chased from the American Type Culture Collection
(Rockville, MD). Another three human RCC cell lines,
A498, ACHN and OS-RC-2 were preserved in our insti-
tute. Immortalized normal human proximal tubule epi-
thelial cell line HK-2 was obtained from the Cell Bank of
Type Culture Collection of Chinese Academy of
Sciences (Shanghai, China). HK-2 cells were cultured in
K-SFM medium (Gibco Life Technologies, Grand Island,
NY), and other cells were cultured in RPMI-1640
medium (HyClone Laboratories, Logan, UT) with 10%
fetal bovine serum (Gibco Life Technologies, Grand
Island, NY), 50U/ml of penicillin and 50 μg/ml of
streptomycin. Human umbilical vein endothelial cells
(HUVEC) were obtained from ScienCell Research La-
boratories (Carlsbad, CA, USA) and cultured in ECM
(Carlsbad, CA, USA). All cells were cultured in a sterile
incubator maintained at 37°C with 5% CO2.
Gene silencing using siRNA
FoxM1 siRNA (GGACCACUUUCCCUACUUU) and
control siRNA (GGACCUGUAUGC GUACAUU) were
purchased from Shanghai Genepharma Co. Ltd. (Shanghai,
China). Cells were Transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Following transfection, the mRNA
and protein levels were assessed 48 hours later.
Real-time quantitative PCR
Total RNA was isolated from tissues and Transfected
cells using TRIzol (Invitrogen) according to the
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synthesized using the High Capacity cDNA Reverse
Transcription Kit (Applied Bios stems, Foster City, CA,
USA). Quantitative real-time PCR was performed using
SYBR Green PCR Master Mix (Applied Bios stems) in a
7900 Real-Time PCR System (Applied Bios stems). β-
actin was used as the reference gene. The following
primers were used: for FoxM1, 5'-AACCGCTACTT
GACATT GG-3' (forward), 5'-GCAGTGGCTTCATCT
TCC-3' (reverse); for CyclinB1, 5'-GGTTGG GTCGG
CCTCTACC T-3' (Forward), 5'-AGCCAGGTGCTG




CAG -3' (Forward), 5'-CCGGAAGAGCTGGTCAATCT
CAGA-3' (Reverse); for p27, 5'-CGCT CGCCAGTC
CATT-3' (Forward), 5'-ACAAAACCGAACAAAA
CAAAG-3' (Reverse); for p21, 5'-TCCAGCGACCTTC
CTCATCCAC-3' (Forward), 5'-TCCATAGCCTCTACT
GCCA CCATC-3' (Reverse); for MMP2, 5'-CCGTGGT
GAGATCTTCTTCT-3' (Forward), 5'-CCTC GTATACC
GCATCAATCT-3' (Reverse); for MMP9, 5'-TTCATCTT
CCAAGGCCAATC-3' (Forward), 5'-CTTGCTGCTGCT
AAAGTTCG-3' (Reverse); for VEGF, 5'-CTCTACCT
CCA CCATGCCAAGT-3' (Forward), 5'-TGATTCTGC
CCTCCTCCTTCT-3' (Reverse). The PCR cycles were
95°C for 10 minutes, followed by 40 cycles of 95°C for
15 seconds and 60°C for 1 minute. Each reaction was
performed in triplicate and analyzed individually. The
results were calculated by using 2-ΔΔCt method.
Western blot assay
Cells and tissues were lysed in lysis buffer containing
protease inhibitor cocktail. Protein concentration was
determined using a Bio-Rad protein assay system (Bio-
Rad, Hercules, CA, USA). Equivalent amounts of pro-
teins were separated by SDS-PAGE, and then transferred
to polyvinylidene difluoride membranes (Bio-Rad). After
being blocked in Tris buffered saline (TBS) containing
5% non-fatmilk, the membranes were incubated with
specific primary antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 4°C for 12 hours and then with
horseradish peroxidase-conjugated anti-rabbit antibody
(Zhongshan, Beijing, China) for 2 hour at room
temperature. Signals were detected on X-ray film using
the ECL detection system (Pierce, Rockford, IL, USA).
The relative protein levels were calculated based on β-
actin as the loading control.
MTT assay
Cells were plated in 96-well culture plates at about 5 ×
103 cells per well 24 hour after transfection. Then, 20 μl
of 5 mg/ml MTT solution was added to each well andincubated for 4 hours at 37°C, the media was removed
from each well, and the resultant MTT formazan was
solubilized in 150 μl of DMSO. The absorbance values
at 490 nm were measured using a microplate reader
(Bio-Rad). The experiment was repeated three times and
each experiment had six replicate wells.
Colony formation assay
Cells were Transfected with control or FoxM1 siRNA
for 48 hours and then plated at 1 × 103 cells/well of a 6-
well plate in triplicate. After 14 days of culture, the col-
onies were fixed with methanol and stained with crystal
violet. The number of colonies per well was counted
using a dissecting microscope with a threshold of 50
cells necessary to constitute a colony. At least two inde-
pendent experiments were performed.
Cell cycle analysis
Cells were harvested 48 hours after transfection with
control or FoxM1 siRNA and fixed in 70% ice-cold etha-
nol overnight. The cells were then washed with PBS, and
stained with propidium iodide (50 mg/ml) in PBS sup-
plemented with RNase (50 mg/ml) in the dark at room
temperature for 30 minutes. Tests were performed in
triplicate for each sample, and analyses of cell cycle dis-
tribution were performed by flow cytometer (FACS Can-
toII, BD Bioscience, USA) in accordance with the
manufacturer’s guidelines.
Gelatin zymography
After transfection with control siRNA or FoxM1 siRNA
for 24 hours, the complete medium was removed, and
the cells were cultured in serum-free medium. After
24 hours, the conditioned medium was harvested, and
then centrifuged to remove the cellular debris and sepa-
rated by 8% acrylamide gels that contained 0.1% gelatin
under non-reducing conditions. Gels were washed in
2.5% Triton X-100 and incubated overnight in 2.5% Tri-
ton X-100 solution at room temperature, with gentle agi-
tation to remove SDS, and then were soaked in reaction
buffer (50 mM Tris-HCl, 200 mM NaCl, 10 mM CaCl2)
at 37°C overnight. After reaction, the gels were stained
with 0.5% Coomassie Brilliant Blue solution, containing
20% methanol and 10% acetic acid, for 1 hour, distained
with 20% methanol and 10% acetic acid, and visualized.
The bands represent the results of gelatinase quantity
and activity.
Enzyme-linked immunosorbent assay (ELISA) for VEGF
Cells (1 × 105) Transfected with control or FoxM1
siRNA were maintained in serum-free medium for
48 hours. The medium was collected, and the concentra-
tions of VEGF in the medium were determined using an
enzyme-linked immunosorbent assay (ELISA) kit (R&D
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Scratch migration assay
Cells were seeded to 12-well plates and Transfected with
control or FoxM1 siRNA. At 24 hours after transfection,
cells were scratched using the tip of a sterile 200-μl pip-
ette (width: ~1 mm) in each well. The plates were
washed twice with PBS in order to remove the detached
cells, and incubated at 37°C in 5% CO2. Wound closure
was monitored at various time points by observation
under a microscope and the degree of cell migration was
quantified by the ratio of gap distance at 24 hours to
that at 0 hour. The experiment was done in triplicate.
Matrigel invasion assay
Cell invasion assay was performed using a 24-well Tran
swell chamber with a pore size of 8 μm (Costar, New
York, NY, USA). The inserts were coated with 50 μl
Matrigel (dilution at 1: 2; BD Bioscience, Franklin Lakes,
NJ, USA). Cells were trypsinised after transfection with
control or FoxM1 siRNA for 48 hours and transferred to
the upper Matrigel chamber in 100 μl of serum free
medium containing 1 × 105 cells and incubated for
24 hours. The lower chamber was filled with medium
that contained 10% fetal bovine serum as chemoattrac-
tants. After incubation, the noninvaded cells on the
upper membrane surface were removed with a cotton
tip, and the cells that passed through the filter were
fixed and stained using 0.1% crystal violet. The numbers
of invaded cells were counted in five randomly selected
high power fields under a microscope. This experiment
was performed in triplicate.
Matrigel in vitro HUVEC tube formation assay
Cells Transfected with control or FoxM1 siRNA were
cultured in serum-free RPMI 1640 for 24 hours. The
conditioned medium were collected, centrifuged and
stored at -20°C until assay. HUVEC (1 × 105 cells/well)
in 500 μl of the indicated conditioned medium were
seeded onto a 24-well plate, which was precoated with
100 μl of growth factor-reduced Matrigel (BD Bio-
science) for 30 minutes. Following stimulation with the
cell conditioned medium for 12 hours, tube formation
was observed under an inverted microscope and
counted. The number of tube formations was measured
by counting the number of tube-like structures formed
by connected endothelial cells in five randomly selected
fields under a microscope. The assay was performed in
triplicate.
Statistical analysis
The statistical analyses were performed using the Statis-
tical Package for the Social Sciences, version 16.0 (SPSSInc., Chicago, IL, USA). A paired-samples t-test was
used to compare FoxM1 mRNA and protein expression
in the ccRCC tissues with that of their paired adjacent
nontumor tissue samples. The relationship between
FoxM1 protein expression and the clinicopathological
features was analyzed using χ2 tests. Overall survival
curves were calculated with the Kaplan-Meier method
and were analyzed with the log-rank test. A Cox propor-
tionalhazards analysis was used in univariate and multi-
variate analyses to explore the effects of FoxM1
expression and ccRCC clinicopathological variables on
survival. Unpaired 2-tailed Student's t-tests were used to
analyze comparisons between the 2 groups. A P-value of
< 0.05 was regarded as statistically significant.
Results
FoxM1 mRNA and protein expression in primary ccRCC
tissue samples and RCC cell lines
We first examined FoxM1 mRNA expression in 39
paired clinical samples from ccRCC patients (tumor tis-
sues and matched adjacent nontumor tissues) by real-
time quantitative PCR. The results revealed a statistically
significant elevation of FoxM1 mRNA in tumors,
as compared to the matched adjacent nontumor tissues
(P < 0.001, Figure 1A). To investigate whether FoxM1
was also elevated at the protein level, western blot was
performed on those 39 paired ccRCC clinical samples.
We found that the protein level of FoxM1 in tumor tis-
sues was significantly higher than that in adjacent non-
tumor tissues (P < 0.001, Figure 1B), consistent with the
results of real-time quantitative PCR. The protein level
of FoxM1 in four representative pairs of samples is
shown in Figure 1C. We also used real-time quantitative
PCR and western blot to detect the expression of FoxM1
mRNA and protein in RCC cell lines as well as in an
immortalized normal human proximal tubule epithelial
cell line. As shown in Figure 1D, the OS-RC-2, Caki-1,
A498, ACHN and 786-O showed higher FoxM1 tran-
script levels relative to the HK-2 normal proximal tubule
epithelial cell line (Figure 1D). Likewise, FoxM1 protein
expression was elevated in those RCC cell lines com-
pared to the HK-2 cell line (Figure 1E).
Immunohistochemical analysis of FoxM1 expression in
ccRCC clinical samples and its relationship to
clinicopathological parameters
We further analyzed FoxM1 protein level in 83 ccRCC
tissues and adjacent nontumor tissues using an immuno-
histochemical approach. FoxM1 protein expression in
tumors was usually increased compared with that in ad-
jacent nontumor tissues. FoxM1 stained mainly in the
cytoplasm of the cells (Figure 2A b-d). 45 (54.2%) cases
showed low FoxM1 expression (FoxM1− or FoxM1+),
and 38 (45.8%) cases exhibited high FoxM1 expression
Figure 1 The expression of FoxM1 mRNA and protein in the human ccRCC surgical specimens and RCC cell lines, as evaluated by real-
time quantitative PCR and western blot. A, The relative mRNA expression of FoxM1 was higher in 39 ccRCC tumor tissues than in matched
adjacent nontumorous tissues (P < 0.001). B, The FoxM1 protein expression was higher in the tumor tissues than in matched adjacent
nontumorous tissues (P < 0.001). C, Expression of FoxM1 protein in four representative pairs of ccRCC tissues is presented. N, nontumorous tissues;
T, ccRCC tissues. D, The FoxM1 mRNA expression in human RCC cell lines was higher in the OS-RC-2, Caki-1, A498, ACHN and 786-O cells,
particularly in the Caki-1 and 786-O cells, compared with the normal proximal tubule epithelial cell line HK-2. E, The FoxM1 protein expression
was elevated in the OS-RC-2, Caki-1, A498, ACHN and 786-O cells compared to the normal proximal tubule epithelial cell line HK-2.
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FoxM1 expression and various clinicopathological para-
meters is described in Table 1. FoxM1 staining level sig-
nificantly correlated with primary tumor stage (P <
0.001), lymph node metastasis (P = 0.01), distant metas-
tasis (P = 0.01), TNM stage (P < 0.001) and histological
grade (P = 0.003). There was no significant association
between FoxM1 expression and patients’ gender and age.
FoxM1 expression and patient survival
The prognostic value of FoxM1 for overall survival in
ccRCC patients was evaluated by comparing the patients
with high and low FoxM1 expression. According to the
Kaplan–Meier survival analysis, ccRCC patients with
high FoxM1 expression had obviously lower overall sur-
vival rates than did those with low FoxM1 expression
(Figure 2B, Log-rank value =27.484, P < 0.001). Univari-
ate and multivariate analyses were conducted using Cox
proportional hazards model to examine the impact of
FoxM1 expression and other clinicopathological para-
meters in ccRCC patients. FoxM1 expression (P < 0.001),
primary tumor stage (P < 0.001), lymph nodes metastasis(P = 0.007), distant metastasis (P < 0.001) and histological
grade (P = 0.01) were significant prognostic factors in
the univariate analysis (Table 2). Multivariate Cox re-
gression analyses showed that advanced primary tumor
stage (P = 0.001), distant metastasis (P = 0.025) and high
FoxM1 expression (P = 0.008) were independent prog-
nostic factors (Table 2). Thus, FoxM1 expression may be
useful for predicting the overall survival of ccRCC
patients.
Effects of FoxM1 depletion on cell growth
In order to determine whether FoxM1 could be an ef-
fective therapeutic target for ccRCC, we employed an
RNA interference approach to knock down its expres-
sion in Caki-1 and 786-O cells expressing high levels of
endogenous FoxM1. The efficacy of FoxM1 siRNA for
knockdown of FoxM1 mRNA and protein was con-
firmed by real-time PCR and western blot analysis, re-
spectively. We observed that FoxM1 mRNA levels were
significantly reduced in cells Transfected with specific
siRNA for FoxM1 compared with those Transfected with
control siRNA (P < 0.01; Figure 3A). Also, the expression
Figure 2 FoxM1 protein expression and patient survival. A, Immunohistochemical analysis of FoxM1 protein expression in 83 cases of ccRCC
tissues: – in a, 1+ in b, 2+ in c, and 3+ in d. Magnification, all × 200. B, Overall survival analysis using the Kaplan–Meier method revealed that
patients with high FoxM1 expression had obviously lower overall survival rates than did those with low FoxM1 expression.
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with the control siRNA-Transfected cells. Thus, the
FoxM1 siRNA could effectively knock down FoxM1 ex-
pression at both transcriptional and translational levels.
We next studied the impact of FoxM1 silencing on cell
proliferation. The results of the MTT assay showed that
down-regulation of FoxM1 significantly reduced the
proliferation rate in both the cell lines tested compared
with the control siRNA-Transfected cells (P < 0.01;
Figure 3B). Colony formation assay further showed
that down-regulation of FoxM1 in two tested cell lines
with transfection of FoxM1 siRNA resulted in a clear
reduction of the colony formation capacity compared
with the control siRNA-Transfected cells (P < 0.05;
Figure 3C). These results from colony formation assay
are consistent with the MTT data, suggesting thatFoxM1 expression influences the growth and prolifera-
tion of ccRCC cells.
Effect of FoxM1 deletion on cell cycle
Cell cycle analysis revealed that FoxM1 silencing in
Caki-1 and 786-O cells caused a accumulation of cells in
the G0-G1 phase and a decrease in the S phase com-
pared with control siRNA-Transfected cells (P < 0.05;
Figure 4A). To investigate the mechanism underlying
the cell cycle arrest, we examined the levels of a few cell
cycle regulatory factors and studied the effects of down-
regulation of FoxM1. As shown in Figure 4B and 4C, the
expression of cyclin B1, cyclin D1, and cyclin-dependent
kinase 2 (Cdk2) at both the mRNA and protein levels
was found to be decreased in cells Transfected with
FoxM1 siRNA compared with those Transfected with
Table 2 Prognostic factors in Cox proportional hazards model
Variable Univariate analysis Multivariate analysis
Risk ratio 95% CI P Risk ratio 95% CI P
Age 0.958 0.506-1.811 0.894
≥57 vs <57
Gender 0.978 0.468-2.042 0.953
male vs female
Histological grade 2.317 1.224-4.388 0.01
G3-4 vs G1-2
Lymph node status 2.787 3.317-5.899 0.007
N1-2 vs N0
Primary tumour stage 6.295 3.190-12.421 <0.001 4.336 1.859-10.116 0.001
T3-4 vs T1-2
Distant metastasis 8.951 3.828-20.930 <0.001 2.950 1.149-7.573 0.025
M1 vs M0
FoxM1 5.505 2.728-11.109 <0.001 3.034 1.337-6.887 0.008
high vs low
Figure 3 Effects of FoxM1 depletion on cell growth. A, FoxM1 mRNA levels were down-regulated by FoxM1 siRNA. B, FoxM1 protein levels
were down-regulated by siRNA. C, Inhibition of cancer cell proliferation by FoxM1 siRNA tested by MTT assay. D, Inhibition of cancer cell colony
formation capacity by FoxM1 siRNA. Experiments were repeated at least three times, and representative data are presented; bars, SD.*, P < 0.05; **,
P < 0.01, relative to control.
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Figure 4 Effect of FoxM1 deletion on cell cycle. A, The cell cycle distribution was analyzed using propidium iodide staining and flow
cytometry. B and C, The expression level of several known cell cycle regulatory factors as detected by real-time quantitative PCR (B) and Western
blotting (C), respectively. The experiments were repeated thrice. *, P < 0.05; **, P < 0.01, relative to control.
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FoxM1 was found to result in an increase in the expres-
sion of cyclin-dependent kinase inhibitors such as p21
and p27. Taken together, these results indicated that
down-regulation of FoxM1 expression suppressed cell
cycle progression in ccRCC cells.
Effect of FoxM1 deletion on MMP-2, MMP-9 and VEGF
As shown in Figure 5A, real-time quantitative PCR ana-
lysis demonstrated that FoxM1 knockdown significantly
decreased MMP-2, MMP-9 and VEGF mRNA expres-
sion compared with control siRNA-Transfected cells
(P < 0.01). Similar results were observed by western blot
analysis as well (Figure 5B). Next, we examined whether
the down-regulation of FoxM1 could also lead to a de-
crease in MMP-2, MMP-9 and VEGF activity. As shown
in Figure 5C, both MMP-2 (Caki-1and 786-O, P < 0.01)
and MMP-9 (P < 0.01 for Caki-1 and P < 0.05 for 786-O)
activities were decreased in the FoxM1 siRNA-
Transfected cells, as determined by gelatin zymography
when compared with control siRNA-Transfected cells.
We also found that VEGF activity was significantlyreduced by the down-regulation of FoxM1, as measured
by ELISA when compared with control siRNA-
Transfected cells (Figure 5D; P < 0.01). These results
clearly suggest that tumor progression could be attenuated
by the down-regulation of FoxM1.
Effect of FoxM1 deletion on migration and invasion
Because FoxM1 silencing inhibited the expression and
activity of MMP-2, MMP-9 and VEGF that are thought
to be critically involved in the processes of tumor cell
migration, invasion and metastasis, we tested the effect
of FoxM1 deletion on cancer cell migration and inva-
sion. In the scratch migration assay, down-regulation of
FoxM1 significantly suppressed the migration of both
Caki-1 and 786-O cells (Figure 6A). The migrating dis-
tance of Caki-1 cells was 0.571 ± 0.055 mm in the con-
trol siRNA group and 0.267 ± 0.041 mm in the FoxM1
siRNA group (P < 0.01). In the 786-O cells, the migrating
distance was 0.547 ± 0.040 mm in the control siRNA
group and 0.283 ± 0.035 mm in the FoxM1 siRNA group
(P < 0.01). Matrigel invasion assay showed that down-
regulation of FoxM1 significantly suppressed the
Figure 5 Effect of FoxM1 deletion on the expression of various cell cycle regulatory factors and MMP-2, MMP-9, and VEGF. A and B,
real-time quantitative PCR and Western blot analysis showed that FoxM1 siRNA inhibited the expression of MMP-2, MMP-9, and VEGF at mRNA
and protein levels in Caki-1 and 786-O cells. C, FoxM1 siRNA inhibited the activity of MMP-2 and MMP-9 based on gelatin zymography assay in
Caki-1 and 786-O cells. D, FoxM1 siRNA inhibited the activity of VEGF in Caki-1 and 786-O cells. The experiments were repeated thrice. *, P < 0.05;
**, P < 0.01, relative to control.
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age cell counts crossing matrigel-coated membrane in
one high power field was 55.7. ± 8.7 for the control
siRNA group and 2.3 ± 0.6 for the FoxM1 siRNA group
of Caki-1 cells (P < 0.01); 77.3 ± 8.1 for the control
siRNA group and 20.6 ± 4.5 for the FoxM1 siRNA group
of 786-O cells (P < 0.01).
Effect of FoxM1 deletion on angiogenesis
Because FoxM1 siRNA inhibited VEGF expression and
activity, we tested whether FoxM1 siRNA-Transfected
cells could reduce the tube formation of HUVECs cul-
tured with conditioned medium (CM), an indirect meas-
ure of angiogenesis. As illustrated in Figure 6C, the CM
obtained from the FoxM1 siRNA-Transfected cells
showed significantly decreased tube formation permicroscopic field as compared to control siRNA-
Transfected cells (Caki-1 control vs FoxM1 siRNA:
17.6 ± 2.7 vs 3.6 ± 1.5, P < 0.01; 786-O control vs
FoxM1 siRNA: 20.2 ± 1.9 vs 3.2 ± 1.6, P < 0.01).
Discussion
Convincing evidence has shown that FoxM1 is upregu-
lated in a wide variety of malignant tumors. FoxM1
overexpression has also been reported to be associated
with worse prognosis and to serve as a prognostic mar-
ker in numerous types of human cancers. However, little
is known about its expression pattern and biological sig-
nificance in ccRCC. In the current study, we showed
that FoxM1 expression determined by real-time quanti-
tative PCR and Western blot was significantly higher in
ccRCC tissues than that in adjacent nontumor renal
Figure 6 FoxM1 siRNA decreased migration and invasion of Caki-1 and 786-O cells, and reduced the HUVECs tube formation. A, Scratch
migration assay showing that FoxM1 siRNA decreased cell migration. B, Matrigel invasion assay showing that FoxM1 siRNA-transfected cells
resulted in low penetration through the Matrigel-coated membrane, compared with control cells. C, Conditioned media from FoxM1 siRNA-
transfected cells were able to significantly reduce the tube formation of HUVECs compared with the medium from control cells. The experiments
were repeated thrice. **, P < 0.01, relative to control.
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that tumor tissues exhibited abundant FoxM1 expres-
sion, in contrast to adjacent nontumor tissues which dis-
played absence or lower FoxM1 expression. To
investigate whether FoxM1 expression might be asso-
ciated with the progression of ccRCC, the FoxM1 ex-
pression levels and the clinic pathologic characteristics
of 83 patients with ccRCC were compared by immuno-
histochemistry. We found that high FoxM1 expression is
significantly correlated with primary tumor stage, lymph
node metastasis, distant metastasis, TNM stage, and
histological grade, suggesting that its expression might
be important for the acquirement of malignant potential
in ccRCCs. Furthermore, elevated FoxM1 expression
was identified as an independent worse prognostic factor
in ccRCC patients. These findings are in agreement with
studies in other human cancers overexpressing FoxM1
[25-30].
We have clearly shown that FoxM1 is highly expressed
in ccRCC cells from patient samples. This prompted us
to examine the biological function of FoxM1 in greaterdetail through in vitro analysis of ccRCC cell lines.
Therefore, we first checked its expression level in several
cell lines and picked up Caki-1 and 786-O with relatively
high FoxM1 level for further study. We employed siRNA
to knockdown FoxM1 expression in these two cell lines.
We found an impaired proliferation capacity and colony
formation ability of both Caki-1 and 786-O cells after
FoxM1 knockdown. We also found that down-regulation
of FoxM1 could inhibit cell migration, invasion, and
angiogenesis. Thus, our study suggested that FoxM1 is a
potential therapeutic target for the treatment of ccRCC.
Abnormal cell proliferation and growth are character-
istics of cancer, including ccRCC. Most of the prolifera-
tive factors influence cell growth by affecting cell cycle
progression. The importance of FoxM1 with respect to
the cell cycle is well recognized. In the present study,
cell cycle analyses revealed that FoxM1 knockdown cells
showed higher levels of G1 phase and lower S phase than
the control cells. So FoxM1 knockdown inhibited G1 to
S transition in cell cycle progression, which might ex-
plain the mechanism of FoxM1 on ccRCC cell
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regulation of FoxM1 caused a marked reduction in cyc-
lin B1, cyclin D1, and Cdk2 expression, which play im-
portant roles in cell cycle progression. We also observed
an increased expression of cyclin-dependent kinase
inhibitors such as p21 and p27 in FoxM1 siRNA-
Transfected cells, which are known to negatively
regulate cell cycle progression. These results suggest that
FoxM1 influences the cell cycle progression by positively
regulating the factors that favor cell cycle progression
and also by negatively influencing the inhibitors of cell
cycle in ccRCC cells.
Metastasis is an important aspect of ccRCC. It is
known that MMPs are involved crucially in the pro-
cesses of tumor cell invasion and metastasis [37,38].
Among these MMPs, MMP-2 and MMP-9 are directly
linked with angiogenesis and degradation of the base-
ment membrane collagen, and their expression and ac-
tivity are correlated with metastatic abilities and
prognosis of cancer [39,40]. FoxM1 has been shown to
be associated with MMP-2 and MMP-9 in multiple
tumor types [31-34]. Here, we showed that down-
regulation of FoxM1 by siRNA in Caki-1 and 786-O
cells led to reduced expression of MMP-2 and MMP-9.
We also found that down-regulation of FoxM1
decreased MMP-2 and MMP-9 activity in the culture
medium based on gelatin zymography assay. These
results suggest that the suppression of FoxM1 expres-
sion has potential for antimetastatic therapy, at least in
part, by inhibiting expression/activity of MMPs.
VEGF is another important factor in tumor cell inva-
sion, angiogenesis, and metastasis. It is well documented
that VEGF is a key mediator of angiogenesis and regu-
lates most of the steps in the angiogenic signal cascade
[41]. Several recent reports have documented a positive
correlation between expression of FoxM1 and VEGF
[31,33,34]. In the present study, we found a significant
reduction in VEGF expression and activity by down-
regulation of FoxM1 using siRNA transfection. These
data suggest that the suppression of FoxM1 expression
has potential for antimetastatic therapy, at least in part,
by inhibiting expression/activity of VEGF.
In order to fully understand the consequences of such
down-regulation in the expression and the activity of
MMP-2, MMP-9 and VEGF, we performed scratch mi-
gration assay and matrigel invasion assay of ccRCC cells
and tube formation assay of HUVECs. We found that
down-regulation of FoxM1 led to a significant reduction
in the migration and invasive potential of Caki-1 and
786-O cells and the tube formation of HUVECs. These
results are consistent with the inactivation of MMP-2,
MMP-9, and VEGF by the down-regulation of FoxM1,
which inhibits cancer cell migration, invasion and angio-
genesis. We recognize some limitations in the article.First, the precise molecular mechanisms of metastasis
promotion by FoxM1 in ccRCC need to be further eluci-
dated. Second, the in vivo metastasis assay should be
performed to further testify the roles of FoxM1 in me-
tastasis of human ccRCC.
Conclusions
In summary, the present study firstly showed that
FoxM1 expression was up-regulated in the majority of
the ccRCC clinical tissue specimens at both mRNA and
protein levels. Higher expression of FoxM1 positively
correlates with the aggressive phenotype of ccRCCs, and
predicts poor survival outcome of patients. We have also
presented experimental evidence that down-regulation
of FoxM1 in ccRCC cell lines using siRNA inhibited cell
proliferation and induced cell cycle arrest with reduced
expression of cyclin B1, cyclin D1, and Cdk2, and
increased expression of p21 and p27. Furthermore,
down-regulation of FoxM1 reduced expression and ac-
tivity of MMP-2, MMP-9, and VEGF, resulting in the in-
hibition of migration, invasion, and angiogenesis. Based
on these findings, we conclude that FoxM1 is function-
ally important in the development and progression of
ccRCC and may serve as a new target for ccRCC
therapy.
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